

| | | | |
|-------------------------|---|---|-------------------------------------|
| Notice to Comply | Application No. 10/076,632 | Applicant(s) Habermann et al. | |
| | Examiner Steadman, D. | Art Unit 1656 | Paper No 200601011 |

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other: A sequence listing with those sequences recited in claims 32-33.

Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216 or (703) 308-2923

For CRF Submission Help, call (703) 308-4212

Patent Software Program Support

Technical Assistance.....703-287-0200

To Purchase Patent Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY



LAW OFFICES OF

SYNNESTVEDT & LECHNER LLP

2600 ARAMARK TOWER
1101 MARKET STREET
PHILADELPHIA, PA 19107-2950
TELEPHONE (215) 923-4466
FACSIMILE (215) 923-2189
E-MAIL synnlech@synnlech.com
www.synnlech.com

December 22, 2006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of P. Habermann
Application No. 10/076,632
Filed February 19, 2002


Art Unit 1652
Examiner D. Steadman
Confirmation No. 2603

Nucleic Acids Encoding Hirudin Fusion Proteins and Methods for Producing Hirudin Fusion Proteins

(Atty. Docket No. P 30,612 USA)

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on Friday, December 22, 2006.



Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT OF SUBSTANCE OF INTERVIEW

Sir:

On October 11, 2006, the undersigned conducted an interview by telephone with the Examiner. The Examiner's February 17, 2006 Action and applicant's June 15, 2006 Reply thereto were discussed. Prior to the interview, the Examiner had reviewed the Reply.

SYNNESTVEDT & LECHNER LLP
U.S. Application No. 10/076,632
Art Unit 1652


December 22, 2006
Attorney Docket No. P 30,612 USA

The Examiner advised that, in view of the amendment to independent Claim 1 submitted in the Reply, it appears that his Section 102 rejection of independent Claim 1 and Claims 7 to 14, 21, and 25 to 28, which are dependent therefrom, has been overcome. The Examiner advised, however, he will conduct a review to determine if there is any additional art which may be relevant to the claims.

The Examiner advised further that he has not been able to fully review applicant's arguments with respect to the Section 112 rejections and that he would require additional time for further consideration thereof.

In addition, the Examiner advised that a revised Sequence Listing must be submitted to include the amino acid sequence recited in Claims 32 and 33 and that he would issue a Notice to Comply.

Respectfully submitted,



Gene J. Yao, Esquire
Reg. No. 47,193
Attorney for Applicants

Synnestvedt & Lechner LLP
2600 Aramark Tower
1101 Market Street
Philadelphia, PA 19107-2950
Tele: (215) 923-4466
Fax: (215) 923-2189

GJY

S:\S\SANOFI-AVENTIS\Patents\P30612 USA\PTO\Interview Summary.doc